Holen Sie sich die Stockscreener-App
1.81
2.69%
-0.05
Handel nachbörslich:
1.76
-0.05
-2.76%
Schlusskurs vom Vortag:
$1.86
Offen:
$1.85
24-Stunden-Volumen:
279.62K
Relative Volume:
1.12
Marktkapitalisierung:
$109.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.86M
KGV:
-1.6161
EPS:
-1.12
Netto-Cashflow:
$-55.66M
1W Leistung:
-10.40%
1M Leistung:
-7.18%
6M Leistung:
+44.80%
1J Leistung:
+6.47%
1-Tages-Spanne:
$1.70
$1.85
1-Wochen-Bereich:
$1.70
$2.1326
52-Wochen-Spanne:
$0.8551
$2.46
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
617-344-4190
Adresse
1210-1220 WASHINGTON STREET, NEWTON
Vergleichen Sie ABOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.81 | 112.67M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Acumen pharma chief regulatory officer sells $2k in shares By Investing.com - Investing.com South Africa
Acumen Pharma president Doherty sells $15k in ABOS stock By Investing.com - Investing.com UK
Acumen Pharma president Doherty sells $15k in ABOS stock - Investing.com
Acumen pharma chief regulatory officer sells $2k in shares - Investing.com
Can Acumen Pharmaceuticals Inc. stock beat market expectations this quarterJuly 2025 WrapUp & Community Trade Idea Sharing - ulpravda.ru
Will Acumen Pharmaceuticals Inc. stock outperform international peersDollar Strength & Advanced Swing Trade Entry Alerts - ulpravda.ru
Will Acumen Pharmaceuticals Inc. stock outperform value stocks2025 Pullback Review & Fast Entry Momentum Alerts - ulpravda.ru
Acumen Pharma CEO O’Connell sells $94k in shares By Investing.com - Investing.com Canada
Acumen Pharma CFO Zuga sells $29k in ABOS stock By Investing.com - Investing.com Canada
Acumen Pharmaceuticals CLO sells $52,689 in shares By Investing.com - Investing.com South Africa
Acumen Pharma CMO Siemers sells $21k in ABOS stock By Investing.com - Investing.com UK
Acumen Pharmaceuticals CLO sells $52,689 in shares - Investing.com
Is Acumen Pharmaceuticals Inc. stock supported by innovation pipelineRisk-Reward Ratio Analysis & Fast Profit Portfolio Plans - ulpravda.ru
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN
Need help Profitable sectors business with absence of listed companiesPrice Channel Trading & Free Real-Time Trading Alerts Every Day - bollywoodhelpline.com
Jindal Steel And Power Can the turnaround happenDividend Cut Warnings & Rapid Portfolio Investment - bollywoodhelpline.com
Arfin India Limited (539151) Quarterly Results Are OutEarnings Revision Updates & Free Gain Edge With Data - bollywoodhelpline.com
ABOS stock touches 52-week low at $1.52 amid market challenges - MSN
Acumen Pharmaceuticals, Inc. (ABOS) AI-Powered Stock Analysis - Meyka
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen - Defense World
Is Acumen Pharmaceuticals Inc. stock a bargain at current levelsJuly 2025 Macro Moves & Technical Confirmation Alerts - DonanımHaber
Can Acumen Pharmaceuticals Inc. stock maintain operating margins2025 Sector Review & Risk Managed Investment Strategies - Улправда
Retail Surge: Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Pullback Review & Fast Entry Momentum Alerts - Улправда
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Downgraded to Sell Rating by Wall Street Zen - Defense World
Is Acumen Pharmaceuticals Inc. stock a dividend growth opportunityJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - Newser
Can Acumen Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Acumen presents new research on Alzheimer’s treatment delivery By Investing.com - Investing.com Canada
Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga
Acumen Pharmaceuticals Presents Results on Alzheimer’s Disease at Conference - Yahoo
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
What analysts say about Acumen Pharmaceuticals Inc stockStock Liquidity Analysis & Invest Like A Pro - earlytimes.in
Acumen Pharmaceuticals highlights enhanced brain delivery technology for oligomer-selective antibodies - marketscreener.com
Acumen presents new research on Alzheimer’s treatment delivery - Investing.com
Acumen (NASDAQ: ABOS) reports CTAD results on 15 to 68-fold delivery and ALTITUDE-AD recruitment - Stock Titan
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Wall Street analysts’ outlook for Acumen Pharmaceuticals Inc (ABOS) - setenews.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts - Defense World
Is Acumen Pharmaceuticals Inc a good long term investmentTrade Execution Strategies & Big Profit Small Investment - earlytimes.in
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2025-11-21 08:02:34 - newser.com
Will Acumen Pharmaceuticals Inc. stock go up soonTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Why Acumen Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - newser.com
Using data models to predict Acumen Pharmaceuticals Inc. stock movementQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
How risky is Acumen Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Is Acumen Pharmaceuticals Inc. stock dividend yield sustainableQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Can Acumen Pharmaceuticals Inc. rally from current levelsTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Acumen Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acumen Pharmaceuticals Inc-Aktie (ABOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Doherty James J. | President and CDO |
Jan 07 '26 |
Sale |
1.99 |
1,700 |
3,379 |
60,500 |
| Schacterle Amy | Chief Regulatory Officer |
Jan 07 '26 |
Sale |
1.98 |
1,097 |
2,176 |
7,703 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):